Merck & Co
Merck & Co to buy Cubist Pharmaceuticals for $8.4 bn
10 Dec 2014
Merck expects the acquisition to add more than $1 billion of revenue after closing in the first quarter, but will be neutral to non-GAAP earnings per share until 2016
Merck & Co in talks to buy Cubist Pharmaceuticals for more than $7 bn
06 Dec 2014
Cubist Pharmaceuticals develops drugs for potentially life-threatening infections caused by dangerous bacteria categorised as serious and urgent public health threats
Merck oncology drug wins ‘breakthrough’ classification by US regulators
28 Oct 2014
Keytruda, Merck & Co's flagship new drug, forms part of a new generation of oncology treatments that use the body’s own immune system to attack and destroy tumours
Merck & Co to sell consumer care business to Germany's Bayer for $14.2 bn
06 May 2014
The deal, which will make Bayer the second-biggest over-the-counter drugs (OTC) maker after Johnson & Johnson, is the largest in the German healthcare industry after Bayer outbid Merck to acquire Schering in 2006 for $21.5 billion
Bayer offers to swap cash and animal health unit for Merck's consumer healthcare
30 Apr 2014
German healthcare major Bayer AG has offered to swap its animal health unit and also pay some cash in exchange for Merck & Co's consumer healthcare business
Bayer, Novartis, Reckitt Benckiser, P&G in fray for Merck & Co's consumer healthcare unit
20 Feb 2014
Bayer, Novartis, Reckitt Benckiser, and Procter & Gamble are among the companies that are exploring a deal to buy Merck &Co's consumer healthcare unit
.webp)
.webp)
